Cargando…

Relevant of neutralizing antibody during SARS-CoV-2 infection and their therapeutic usage

Detalles Bibliográficos
Autores principales:	Gupta, Sneh Lata, Jaiswal, Rishi K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123622/ https://www.ncbi.nlm.nih.gov/pubmed/35596816 http://dx.doi.org/10.1007/s11033-022-07493-z

Ejemplares similares

Neutralizing antibody: a savior in the Covid-19 disease
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Children’s SARS-CoV-2 Infection and Their Vaccination
por: Gupta, Sneh Lata, et al.
Publicado: (2023)

Searching for escape-resistant anti–SARS-CoV-2 neutralizing antibodies
por: Mahla, Ranjeet Singh, et al.
Publicado: (2022)

Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development
por: Cohen, Samuel A., et al.
Publicado: (2020)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
por: Wang, Bei, et al.
Publicado: (2021)

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
por: Lv, Zhe, et al.
Publicado: (2020)

Immunotherapy: an alternative promising therapeutic approach against cancers
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Neutralizing antibodies for SARS-CoV-2 infection
por: Berenguer, Juan
Publicado: (2022)

The Role of Antibody Testing for SARS-CoV-2: Is There One?
por: Theel, Elitza S., et al.
Publicado: (2020)

Waning antibodies to SARS-CoV-2 – Don't panic
por: Meyer, Benjamin
Publicado: (2021)

Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2
por: Zhou, Xiaojuan, et al.
Publicado: (2021)

SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2
por: Wang, Ruoke, et al.
Publicado: (2022)

An Assessment of the Bivalent Vaccine as a Second Booster for COVID-19
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Neutralizing antibody titres in SARS-CoV-2 infections
por: Lau, Eric H. Y., et al.
Publicado: (2021)

Antibody-mediated neutralization of SARS-CoV-2
por: Gruell, Henning, et al.
Publicado: (2022)

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection
por: Lin, Qingqing, et al.
Publicado: (2020)

Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
por: Zhou, Guangyu, et al.
Publicado: (2020)

Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
por: Liu, Mingtao, et al.
Publicado: (2023)

SARS-CoV-2 antibody-based SURVEILLANCE: New light in the SHADOW
por: Plebani, Mario
Publicado: (2020)

Using SARS-CoV-2 Antibody Testing in COVID-19 Research
por: Amraotkar, Alok R., et al.
Publicado: (2023)

SARS-CoV-2 re-infection, vaccination and neutralizing antibodies
por: Bongiovanni, Marco, et al.
Publicado: (2022)

SARS-CoV-2 neutralizing antibody development strategies
por: BALCIOĞLU, Bertan Koray, et al.
Publicado: (2020)

Human antibodies can neutralize SARS-CoV-2
por: Catalan-Dibene, Jovani
Publicado: (2020)

Neutralizing and enhancing antibodies against SARS-CoV-2
por: Liu, Yafei, et al.
Publicado: (2022)

Twelve lateral flow immunoassays (LFAs) to detect SARS-CoV-2 antibodies
por: Owen, Sophie I., et al.
Publicado: (2022)

Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
por: Takeshita, Masaru, et al.
Publicado: (2022)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
por: Liu, Hejun, et al.
Publicado: (2021)

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
por: Liu, Hejun, et al.
Publicado: (2021)

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
por: Wajnberg, Ania, et al.
Publicado: (2020)

Persistence of the neutralizing antibody response after SARS-CoV-2 infection
por: Shim, Sang-Mu, et al.
Publicado: (2022)

SARS-CoV-2 Monoclonal Antibodies in Children: Ethical Considerations
por: Wolfe, Ian D., et al.
Publicado: (2021)

SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T cell recognition
por: Altmann, Daniel M., et al.
Publicado: (2021)

Mucosal immunity to SARS-CoV-2: a clinically relevant key to deciphering natural and vaccine-induced defences
por: Matuchansky, Claude
Publicado: (2021)

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
por: Chen, Peter, et al.
Publicado: (2020)

Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
por: Wang, Shuang, et al.
Publicado: (2020)

Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters
por: Piepenbrink, Michael S., et al.
Publicado: (2021)

Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages
por: Touret, Franck, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mv4rrhoudgapbi17dp3rd32sks